Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

United-Guardian Q3 revenue rises on Renacidin sales, net income jumps

By Reuters News


Overview

  • US life sciences and personal care supplier's Q3 revenue rose 54% yr/yr, net income up 247%

  • Growth driven by higher pharmaceutical, cosmetic ingredient, and medical lubricant sales

  • Expanded formulary coverage for Renacidin contributed to pharmaceutical sales growth


Outlook

  • Company plans new marketing efforts to boost awareness of Renacidin among healthcare professionals

  • United-Guardian expects to launch a new personal care product early next yr


Result Drivers

  • RENACIDIN SALES - Pharmaceutical sales rose 29% yr/yr, mainly due to increased Renacidin sales after expanded formulary coverage

  • COSMETIC INGREDIENTS - Cosmetic ingredient sales jumped 187% yr/yr, led by higher purchases from Ashland Specialty Ingredients

  • MEDICAL LUBRICANTS - Medical lubricant sales increased 20% yr/yr, driven by higher orders from a customer in India


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

$3.49 mln

Q3 EPS

$0.20


Reuters Recommended Reads

  • Nov 9 - Ionis Pharmaceuticals Q3 revenue rises 55%

  • Nov 9 - Israel's Kamada Q3 revenue up 11%, raises forecast

  • Nov 9 - ImmunityBio Q3 revenue rises on Anktiva sales growth but misses estimates


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.
 

Cryptocurrency-related content is intended solely as news and market commentary. Crypto Derivatives are not available to Retail clients registered with Capital Com (UK) Ltd.